| Autor: |
Estabrook, Mark, Hackel, Meredith, Stone, Gregory, Perez, Katherine, Sahm, Daniel |
| Zdroj: |
Journal of Global Antimicrobial Resistance; December 2024, Vol. 39 Issue: 1, Number 1 Supplement 1 p12-12, 1p |
| Abstrakt: |
Aztreonam-avibactam is approved in the European Union for treatment of hospital/ventilator acquired bacterial pneumonia, complicated intraabdominal infection, complicated urinary tract infection and infections where treatment options are limited. Aztreonam is stable to hydrolysis by metallo-β-lactamases (MBLs), while avibactam inhibits class A and C β-lactamases, often co-carried by MBL-positive isolates, that inactivate aztreonam. This study examined the activity of aztreonam-avibactam and comparators against Enterobacterales carrying carbapenemases collected in 2018-2022 as part of the ATLAS surveillance program. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Full Text from ScienceDirect